Skip NavigationSkip to Content
Return Return to Search Results

Efficacy of antibody-based therapies against Middle East respiratory syndrome coronavirus (MERS-CoV) in common marmosets

  1. Author:
    van Doremalen, Neeltje
    Falzarano, Darryl
    Ying, Tianlei
    de Wit, Emmie
    Bushmaker, Trenton
    Feldmann, Friederike
    Okumura, Atsushi
    Wang, Yanping
    Scott, Dana P
    Hanley, Patrick W
    Feldmann, Heinz
    Dimitrov, Dimiter
    Munster, Vincent J

  2. Author Address

    Virus Ecology Unit, Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, MT, USA., Disease Modeling and Transmission, Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, MT, USA., Protein Interactions Section, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA., Rocky Mountain Veterinary Branch, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, MT, USA., Disease Modeling and Transmission, Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, MT, USA; Department of Microbiology, University of Washington, Seattle, WA, USA., Virus Ecology Unit, Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, MT, USA. Electronic address: munstervj@niaid.nih.gov.,
    1. Year: 2017
    2. Date: Jul
    3. Epub Date: 2017 Apr 04
  2. Journal: Antiviral Research
    1. 143
    2. Pages: 30-37
  4. Type of Article: Article
  5. ISSN: 0166-3542
  1. Abstract:

    Cases of Middle East respiratory syndrome coronavirus (MERS-CoV) continue to be identified and with a lack of effective clinical treatment and no preventative strategies, treatment using convalescent plasma or monoclonal antibodies (mAbs) is a potential quick route to an intervention. Passive immunotherapy via either convalescent plasma or mAbs has proven to be effective for other infectious agents. Following infection with MERS-CoV, common marmosets were treated with high titer hyperimmune plasma or the mAb m336, at 6 and 48 h post inoculation. Both treatments reduced signs of clinical disease, but reduction in viral loads in the respiratory tract were only found in the hyperimmune plasma group. A decrease in gross pathology was found only in the mAb-treated group, but no histological differences were observed between treated and control animals. While both hyperimmune plasma and the m336 treatments reduced the severity of disease in the common marmoset, neither treatment resulted in full protection against disease. Copyright © 2017. Published by Elsevier B.V.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1016/j.antiviral.2017.03.025
  3. PMID: 28389142
  4. View record in Web of Science®
  5. WOS: 000402947100004

Library Notes

  1. Fiscal Year: FY2016-2017
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel